Zhongzhi Pharmaceutical Holdings Limited

SEHK:3737 Stok Raporu

Piyasa değeri: HK$837.7m

Zhongzhi Pharmaceutical Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Zhongzhi Pharmaceutical Holdings CEO'su Ying Feng Lai, Mar2021 tarihinde atandı, in görev süresi 3.67 yıldır. in toplam yıllık tazminatı CN¥ 1.39M olup, şirket hissesi ve opsiyonları dahil olmak üzere 79% maaş ve 21% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.69% ine doğrudan sahiptir ve bu hisseler HK$ 5.81M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.7 yıl ve 9.4 yıldır.

Anahtar bilgiler

Ying Feng Lai

İcra Kurulu Başkanı

CN¥1.4m

Toplam tazminat

CEO maaş yüzdesi79.0%
CEO görev süresi3.7yrs
CEO sahipliği0.7%
Yönetim ortalama görev süresi3.7yrs
Yönetim Kurulu ortalama görev süresi9.4yrs

Son yönetim güncellemeleri

Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

May 10
Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

Recent updates

Little Excitement Around Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Earnings As Shares Take 26% Pounding

Aug 22
Little Excitement Around Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Earnings As Shares Take 26% Pounding

Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)

Jun 19
Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)

Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

May 10
Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

May 05
Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Apr 21
Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

Feb 01
Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

May 24
These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

Aug 26
Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

Apr 28
Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Jun 11
These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

May 06
Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Apr 21
Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

Mar 29
Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Mar 05
The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Feb 15
Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?

Jan 14
What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?

Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?

Dec 27
Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?

If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late

Dec 14
If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late

Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?

Nov 30
Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 17
Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

CEO Tazminat Analizi

Ying Feng Lai'un ücretlendirmesi Zhongzhi Pharmaceutical Holdings'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

CN¥111m

Mar 31 2024n/an/a

CN¥137m

Dec 31 2023CN¥1mCN¥1m

CN¥163m

Sep 30 2023n/an/a

CN¥164m

Jun 30 2023n/an/a

CN¥164m

Mar 31 2023n/an/a

CN¥135m

Dec 31 2022CN¥1mCN¥802k

CN¥106m

Sep 30 2022n/an/a

CN¥84m

Jun 30 2022n/an/a

CN¥63m

Mar 31 2022n/an/a

CN¥57m

Dec 31 2021CN¥1mCN¥791k

CN¥52m

Sep 30 2021n/an/a

CN¥93m

Jun 30 2021n/an/a

CN¥133m

Mar 31 2021n/an/a

CN¥136m

Dec 31 2020CN¥1mCN¥801k

CN¥139m

Sep 30 2020n/an/a

CN¥133m

Jun 30 2020n/an/a

CN¥128m

Mar 31 2020n/an/a

CN¥121m

Dec 31 2019CN¥986kCN¥700k

CN¥115m

Sep 30 2019n/an/a

CN¥106m

Jun 30 2019n/an/a

CN¥97m

Mar 31 2019n/an/a

CN¥91m

Dec 31 2018CN¥603kCN¥274k

CN¥85m

Tazminat ve Piyasa: Ying Feng 'ın toplam tazminatı ($USD 191.40K ) Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 233.55K ).

Tazminat ve Kazançlar: Ying Feng şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.


CEO

Ying Feng Lai (32 yo)

3.7yrs

Görev süresi

CN¥1,385,000

Tazminat

Mr. Ying Feng Lai has been Executive Director of Zhongzhi Pharmaceutical Holdings Ltd since May 14, 2018 and serves as its Chief Executive since March 24, 2021. Mr. Lai joined the Group since April 2014 an...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Zhi Tian Lai
Chairman9.8yrsCN¥1.92m60.33%
HK$ 505.4m
Ying Feng Lai
Chief Executive & Executive Director3.7yrsCN¥1.39m0.69%
HK$ 5.8m
Ying Sheng Lai
CFO & Executive Director3.7yrsCN¥1.16mVeri yok
Xiao Jun Cao
Deputy GM & Executive Director3.7yrsCN¥1.36m0.38%
HK$ 3.1m
Wing Yan Ho
Company Secretary7.5yrsVeri yokVeri yok

3.7yrs

Ortalama Görev Süresi

42yo

Ortalama Yaş

Deneyimli Yönetim: 3737 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.7 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Zhi Tian Lai
Chairman9.8yrsCN¥1.92m60.33%
HK$ 505.4m
Ying Feng Lai
Chief Executive & Executive Director6.5yrsCN¥1.39m0.69%
HK$ 5.8m
Ying Sheng Lai
CFO & Executive Director2.7yrsCN¥1.16mVeri yok
Xiao Jun Cao
Deputy GM & Executive Director9.8yrsCN¥1.36m0.38%
HK$ 3.1m
Kwun Wan Ng
Independent Non-Executive Director9.4yrsCN¥162.00kVeri yok
Li Xia Jiang
Non-Executive Director10.2yrsCN¥270.00k4.89%
HK$ 41.0m
Kam Wah Wong
Independent Non-Executive Director9.4yrsCN¥162.00kVeri yok
Dai Han Zhou
Independent Non-Executive Director9.4yrsCN¥162.00kVeri yok

9.4yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 3737 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.4 yıldır).